RxDoctor Payments DataLook up a doctor →

Ryan Drake, DO

Neurology · Canton, OHNPI 1326256462

Payments from drug & device makers

$5,464,148in general payments, 2019–2025

Across 2,542 payments — averaging $2149.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.7M
  • Eisai Inc.$473K
  • Alkermes, Inc.$201K
  • Avadel CNS Pharmaceuticals, LLC$167K
  • Lilly USA, LLC$108K
  • Harmony Biosciences LLC$100K
  • plus $685K from 54 others
$74,842in research payments, 2019–2025

Across 15 payments — averaging $4989.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$72K
  • Amneal Pharmaceuticals LLC$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly50$3,728,630
Eisai Inc.164$473,272
Alkermes, Inc.140$201,023
Avadel CNS Pharmaceuticals, LLC16$166,616
Lilly USA, LLC151$108,158
Harmony Biosciences LLC70$100,403
AstraZeneca(2 entities)139$87,709
Teva Pharmaceuticals USA, Inc.136$72,429
Novartis95$60,471
Novo Nordisk AS35$49,017
Amgen(2 entities)99$48,234
Otsuka Pharmaceutical Development & Commercialization, Inc.7$39,576
SK Life Science, Inc.127$35,709
AbbVie(2 entities)243$33,487
Genentech, Inc.7$33,047
Neurocrine Biosciences, Inc.80$32,831
Biogen51$32,017
Alnylam Pharmaceuticals Inc.25$24,091
Avanir Pharmaceuticals, Inc.12$23,291
EMD Serono, Inc.101$22,063
Biohaven Pharmaceuticals, Inc.19$15,736
H. Lundbeck A S6$15,589
Jazz Pharmaceuticals Inc.69$11,095
Bristol Myers Squibb23$10,724
UCB, Inc.90$8,098
Argenx US, Inc.23$7,684
Roche Products Limited2$7,400
Merck6$2,655
E.r. Squibb & Sons, L.L.C.7$1,574
Amneal Pharmaceuticals LLC19$1,437
Ares Trading SA12$941
Sanofi35$786
Pfizer68$775
Lundbeck LLC36$734
TG Therapeutics, Inc.34$633
Genentech USA, Inc.46$627
Acadia Pharmaceuticals Inc30$589
Johnson & Johnson(2 entities)27$583
Kyowa Kirin, Inc.22$424
Axsome Therapeutics, Inc.14$306
Vanda Pharmaceuticals Inc.14$293
Sunovion Pharmaceuticals Inc.22$271
Xeris Pharmaceuticals, Inc.14$241
Biohaven Pharmaceutical Holding Company Ltd.12$228
Takeda Pharmaceuticals U.S.A., Inc.9$226
Neurelis, Inc.11$210
Sumitomo Pharma America, Inc.12$138
Avion Pharmaceuticals8$123
Acorda Therapeutics, Inc6$111
Grifols USA, LLC5$109
Neuropace, Inc.2$103
Tanabe Pharma America, Inc.6$101
Upsher-smith Laboratories LLC4$101
GE HealthCare8$99
C2n Diagnostics, LLC2$90
Supernus Pharmaceuticals, Inc.4$85
Corium, LLC3$84
Catalyst Pharmaceuticals, Inc.4$76
Impel Pharmaceuticals Inc.4$68
Scilex Pharmaceuticals Inc.4$68

How this compares

$5,464,148 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024
$346,923
Medicare patients
651
Services billed
41,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Canton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →